Press release
GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity
GM1 Gangliosidosis Market
Projected Growth and Market Size of the GM1 Gangliosidosis Market by 2030
The GM1 gangliosidosis market is anticipated to experience rapid expansion, reaching a value of $0.96 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 10.8%. Several factors are driving this upward trajectory, including advances in the gene therapy pipeline, incentives designed for orphan drugs, better diagnostic screening methods, increased patient advocacy efforts, and growing funding from biotechnology sectors. Notable trends expected during the forecast period involve a stronger emphasis on developing drugs for rare diseases, enhanced research in gene therapy, broader application of enzyme replacement therapies, expansion in newborn genetic screening programs, and increased clinical trial activities.
The gm1 gangliosidosis market size has grown rapidly in recent years. It will grow from $0.57 billion in 2025 to $0.63 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rare disease research initiatives, enzyme deficiency identification, advances in genetic diagnostics, hospital-based pediatric care, early clinical studies.
Download a free sample of the gm1 gangliosidosis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR
Key Players Leading the GM1 Gangliosidosis Market
Several major pharmaceutical and biotechnology companies are active within the GM1 gangliosidosis market. Prominent names include Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, and Sangamo Therapeutics Inc.
Collaborations Accelerating Pediatric Gene Therapy Development
In August 2024, Passage Bio Inc., a biotechnology firm based in the United States, announced a partnership with GEMMA Biotherapeutics to advance gene therapies focused on pediatric populations. The collaboration involves the out-licensing of three gene therapies targeting lysosomal storage diseases: PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy. GEMMA Biotherapeutics specializes in developing genetic medicines for rare pediatric disorders, and this collaboration aims to accelerate the availability of innovative treatments.
View the full gm1 gangliosidosis market report:
https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR
Strategic Partnerships Shaping the Future of GM1 Gangliosidosis Therapy
Leading companies in the GM1 gangliosidosis field are increasingly relying on strategic partnerships to maintain market leadership and promote innovation. These alliances pool together expertise, resources, and technology to speed up research, clinical trials, and product commercialization. For example, in October 2024, GEMMA Biotherapeutics forged a partnership with the Oswaldo Cruz Foundation (Fiocruz), a Brazilian health research institution. This deal includes up to $100 million in funding from Fiocruz for clinical research and manufacturing efforts focused on gene therapies for rare diseases, including GM1 gangliosidosis. Importantly, this collaboration seeks to ensure broader access by integrating treatments into Brazil's public healthcare system and emphasizing technology transfer to make these therapies available beyond affluent regions.
Comprehensive Segmentation of the Global GM1 Gangliosidosis Market
The GM1 gangliosidosis market is segmented across several dimensions to provide detailed insights:
1) Disease Type:
- Type 1 GM1 Gangliosidosis
- Type 2 GM1 Gangliosidosis
- Type 3 GM1 Gangliosidosis
2) Treatment Modalities:
- Anticonvulsants
- Bone Marrow Transplantation
- Cord-Blood Hematopoietic Stem-Cell Transplantation
- Enzyme Replacement
- Gene Therapy
3) End-User Categories:
- Research Institutes
- Hospitals
- Other End-Users
Further breakdowns include:
- Type 1 GM1 Gangliosidosis subdivided into Classic Infantile Onset and Atypical Infantile Onset
- Type 2 GM1 Gangliosidosis divided into Classic Juvenile Onset and Atypical Juvenile Onset
- Type 3 GM1 Gangliosidosis categorized into Classic Adult Onset and Atypical Adult Onset
This detailed segmentation aids in understanding the market dynamics and targeting treatment development more effectively.
Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity here
News-ID: 4607707 • Views: …
More Releases from The Business Research Company
Hashimotos Disease Market Research Reveals Path To $2.27 Billion By 2030
The Hashimoto's Disease market is gaining increased attention as awareness about autoimmune thyroid conditions grows. With advancements in medical research and digital health technologies, this sector is poised for steady expansion in the coming years. Let's explore the market's projected growth, key players, and important segments shaping its future.
Forecasted Growth and Market Size for Hashimoto's Disease
The Hashimoto's disease market is projected to experience substantial growth, reaching a valuation…
Hair Restoration Market Demonstrates Long-Term Growth Potential At 11.9% CAGR
The hair restoration industry is on the brink of significant expansion as demand for innovative treatments and advanced technologies continues to rise. With a growing focus on regenerative medicine and minimally invasive procedures, this market is set to evolve rapidly over the coming years. Let's explore the current market size, key players, trends, and segmentation that are shaping the future of hair restoration.
Projected Growth and Market Size of the Hair…
Hair Drug Testing Market Outlook Signals Expansion To $3.4 Billion Through 2030
The hair drug testing sector is on the verge of remarkable expansion, driven by technological advancements and increasing demand across various industries. As concerns about workplace safety and compliance intensify, the market is responding with innovative solutions that promise greater accuracy and efficiency. Below, we explore the market's anticipated size, key players, prevailing trends, and segmentation details shaping this evolving landscape.
Anticipated Growth and Market Size of the Hair Drug Testing…
Gynecology Robotic Surgery Market Report 2026 Market Outlook Supported By A Fore …
The gynecology robotic surgery market is on track for significant expansion over the coming years, driven by technological advances and shifting clinical practices. As surgical robotics becomes increasingly sophisticated and widely adopted, the landscape of gynecological care is evolving toward less invasive and more precise procedures. The following sections explore the market's size, key players, emerging trends, and segmentation in detail.
Projected Market Growth and Future Outlook for Gynecology Robotic Surgery…
More Releases for GM1
GM1 Gangliosidosis Treatment Market (2026) | GM1 Gangliosidosis Type 2 (Juvenile …
DataM Intelligence has released a new research report titled "GM1 Gangliosidosis Treatment Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in…
Leading Companies Fueling Innovation and Growth in the GM1 Gangliosidosis Market
Exploring the Future Growth of the GM1 Gangliosidosis Market
The GM1 gangliosidosis market is poised for significant expansion over the coming years. Forecasts predict the market will reach $0.96 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.8%. This upward trend is supported by advancements in the gene therapy pipeline, incentives for orphan drug development, enhanced diagnostic screening methods, stronger patient advocacy efforts, and increased…
GM1 Gangliosidosis Market Expected to Reach USD 1.6 Billion by 2034
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme. This results in the accumulation of GM1 gangliosides in cells, primarily affecting the central nervous system. The disease is classified into infantile, juvenile, and adult-onset forms, with infantile GM1 being the most severe and often fatal in early childhood.
Download Full PDF Sample Copy of Market Report…
GM1 Gangliosidosis Market Massive Growth opportunity Ahead
GM1 Gangliosidosis Market Outlook 2024-2034: Expanding Research, Orphan Drug Approvals, and Regional Growth
Introduction
GM1 Gangliosidosis is an ultra-rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to progressive neurodegeneration. Patients experience a range of symptoms-from developmental delays and skeletal abnormalities to severe motor dysfunction and premature mortality. With no approved curative therapy to date, treatment options remain largely supportive.
However, the last decade has witnessed a surge in…
GM1 Gangliosidosis Market Size And Global Industry Forecast 2034
Introduction
The GM1 Gangliosidosis Market is gaining attention as advancements in genetic research and rare disease drug development open new possibilities for this ultra-rare lysosomal storage disorder. GM1 gangliosidosis is caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme and progressive neurodegeneration. With no approved curative treatments currently available, ongoing innovation in gene therapy, enzyme replacement therapy (ERT), and small molecule chaperones is fueling significant…
GM1 Gangliosidosis Treatment Market
The GM1 Gangliosidosis Treatment Market is expected to witness substantial growth during the forecast period of 2023-2030. Here's an overview of the dynamics, segment analysis, geographical share, and impact of COVID-19 and the Russia-Ukraine war:
Market Overview:
The global GM1 gangliosidosis treatment market is anticipated to experience significant growth due to factors such as rising lysosomal storage disorders, increased research and development activities, and government investments in pharmaceuticals and biotechnology.
Market Dynamics:
Drivers:
Government Investments…
